|Dr. Silviu Itescu||Founder, CEO, MD, Chairman of Scientific Advisory Board & Exec. Director||2.03M||N/A||1957|
|Dr. Donna L. Skerrett||Chief Medical Officer||N/A||N/A||1957|
|Mr. Roger D. Brown BA||Head of Spinal Orthopedic Disorders||N/A||N/A||N/A|
|Mr. Michael Schuster MS, BSc, MBA||Head of Pharma Partnering||N/A||N/A||1977|
|Dr. Kenneth M. Borow M.D.||Exec.||N/A||N/A||1948|
Mesoblast Limited, a biopharmaceutical company, develops and commercializes allogeneic cellular medicines. Its proprietary regenerative medicine technology platform is based on specialized cells known as mesenchymal lineage adult stem cells. The company's products under the Phase III clinical trials include MSC-100-IV for steroid refractory acute graft versus host disease; MPC-150-IM for advanced heart failure; and MPC-06-ID for chronic low back pain due to degenerative disc disease. It is also developing MPC-300-IV that is in Phase II clinical trials for the treatment of biologic refractory rheumatoid arthritis, diabetic kidney diseases, and type 2 diabetic nephropathy. It operates in the United States, Australia, Singapore, the United Kingdom, and Switzerland. Mesoblast Limited has strategic partnerships with Tasly Pharmaceutical Group to offer MPC-150-IM for heart failure and MPC-25-IC for heart attacks in China; and JCR Pharmaceuticals Co. Ltd. for the treatment of wound healing in epidermolysis bullosa. The company was founded in 2004 and is headquartered in Melbourne, Australia.
Mesoblast Limited’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.